Project Details
Description
This study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with alectinib in real-world clinical practice.
| Acronym | ReAlec |
|---|---|
| Status | Active |
| Effective start/end date | 10/05/21 → 10/05/27 |
Collaborative partners
- Hoffmann-La Roche Inc. (lead)
- Mediclinic Airport Road Hospital
- Mediclinic City Hospital
- Abu Dhabi Health Services Company
Keywords
- ALK-positive NSCLC
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplasms by Site
- Neoplasms
- Lung Diseases
- Respiratory Tract Diseases
- Carcinoma, Non-Small-Cell Lung
- Tyrosine Kinase Inhibitors
- Protein Kinase Inhibitors
- Enzyme Inhibitors
- Molecular Mechanisms of Pharmacological Action
- Alectinib
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.